Court will not force DEA to schedule Fycompa

The U.S. Court of Appeals for the District of Columbia denied a request from Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) asking the court to direct the U.S. Drug Enforcement Agency to schedule Fycompa perampanel within a set timeline. FDA approved the epilepsy drug in October 2012 and sent its scheduling recommendation to the DEA in January. In August, Eisai asked the court to direct the agency to schedule Fycompa. DEA has not yet scheduled the AMPA-type glutamate receptor antagonist, but in a letter to the court said it expects to issue a notice of proposed rulemaking for Fycompa by the end of October (see BioCentury Extra, Aug. 19). ...